Positive results for combination of ribociclib and letrozole in patients with recurrent low-grade serous ovarian cancer
The GOG Foundation, Inc. (GOG) announced positive results from an investigator-initiated phase II trial, sponsored by the GOG, investigating the combination of ribociclib and letrozole in patients with recurrent low-grade ...
Mar 27, 2023
0
5